FDA approved Novartis' Rhapsido (remibrutinib) for symptomatic dermographism based on Phase III data showing 29.3% complete hive resolution at Week 12 vs 14.0% placebo. Safety consistent with CSU. Now approved for both CSU and SD.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
